Acute and Two-week Effects of Spiolto Respimat (Tiotropium/Olodaterol) on Cardiac Function, the Autonomic Nervous System and Small Airway Function in Hyperinflated COPD Subjects
Latest Information Update: 28 Apr 2023
At a glance
- Drugs Olodaterol/tiotropium bromide (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- 27 Apr 2023 This trial has been discontinued (End Date: 18 Apr 2023), according to European Clinical Trials Database record.
- 25 Apr 2023 Status changed from recruiting to completed.
- 09 Jan 2023 Planned End Date changed from 1 Oct 2022 to 1 Jun 2023.